Pharmacological studies indicate that spinal p38 mitogen-activated protein kinase plays a role in the development of hyperalgesia. We investigated whether either the spinal isoform p38a or p38b is involved in peripheral inflammation evoked pain state and increased expression of spinal COX-2. Using intrathecal antisense oligonucleotides, we show that hyperalgesia is prevented by downregulation of p38b but not p38a, whereas increases in spinal COX-2 protein expression at 8 hours are mediated by both p38a and b isoforms. These data suggest that early activation of spinal p38b isoform may affect acute facilitatory processing, and both p38b and a isoforms mediate temporally delayed upregulation of spinal COX-2. NeuroReport
Introduction
Earlier studies have shown that intrathecal (IT) delivery of inhibitors of p38 mitogen-activated protein kinase (p38) attenuate hyperalgesia including that produced by intraplantar carrageenan or ITsubstance P (SP) [1] . Importantly, IT p38 inhibitors, at analgesic doses, also block spinal prostaglandin 2 release and prevent delayed increases otherwise observed in spinal COX-2 expression [1] [2] [3] . There are, however, at least four different p38 isoforms (a, b, g, and d) expressed in adult mammalian central nervous system [4] . Although the p38 isoforms share certain structural and enzymatic properties, only p38a and p38b are sensitive to the conventional p38 inhibitors (SB203580, SD-282 [5] ) known to alter pain processing. As p38a and p38b are both expressed in spinal dorsal horn [3] , the question arises as to which, if not both, isoform is relevant to these two actions. In this study we examined the effects of IT treatment with antisense (AS) oligonucleotides, targeted at the respective p38a and p38b isoform, on the thermal hyperalgesia produced by intraplantar carrageenan and IT SP-induced delayed spinal COX-2 expression in rats.
Materials and methods

Animals and intrathecal drug delivery
These experiments were carried out according to the protocols approved by the Institutional Animal Care Committee of University of California, San Diego. Male Holzman Sprague-Dawley rats (300-350 g) were prepared with lumbar IT catheters (PE-5, 8.5 cm) [6] . Intrathecal oligonucleotides were administered, starting 5-6 days after surgery.
Three oligonucleotides (ISIS Pharmaceuticals Inc., Carlsbad, California and Altair Therapeutics Inc., San Diego, California, USA) were used. ISIS 101757 (AGGTGCTCAGGACTCCA TTT) is an AS oligonucleotide that hybridizes to rat p38a mRNA (a-AS) beginning at position 1081, whereas ISIS 107211 (GTATGTCCTCCTCGCGTGGA) is a p38b-AS oligonucleotide that hybridizes with the target beginning at position 439 of p38bmRNA. ISIS 141923 (CCTTC CCTGAAGGTTCCTCC) is a missense (MS) control. Both AS(s) and MS compounds are synthetic 20-mer oligonucleotides, with a full phosphorothioate backbone and 2 0 -O-methoxyethyl modifications at positions of the ribose at nucleobases 1-5 and 16-20. Oligonucleotides were dissolved in artificial cerebrospinal fluid and administered IT (30 mg in 10 ml artificial cerebrospinal fluid) once daily for 5 days. Behavioral experiments and spinal tissue collection were performed on day 6.
Assessment of thermal nociception
Local inflammation was produced by unilateral injection of carrageenan (lambda, Sigma, St. Louis, Missouri, USA, 100 ml, 2% in saline) into the plantar surface of the left hind paw during brief isoflurane anesthesia (2-4%). To assess thermally evoked paw withdrawal response, a
Hargreaves type device was used [7] . Basal paw withdrawal latencies were assessed at time = -30 min and carrageenan injected intraplantarly at time = 0 min. Withdrawal latencies were assessed periodically. Response data were presented as response latency versus time and statistical analysis was undertaken using the hyperalgesic index (% change from precarrageenan baseline Â min).
Western blot analysis
To verify the effect of IT AS on target protein expression, p38a, and b were measured in cords after 5-day IT AS/MS treatment. COX-1 and COX-2 expression was examined in spinal cords of rats harvested 8 h after IT bolus SP (60 nmol) day 6 after 5-day AS or MS treatment. Lumbar spinal cords were homogenized by sonication in extraction buffer (50 mM Tris buffer), containing 0.5% Triton X-100, 150 mM NaCl, 1 mM EDTA, protease inhibitor cocktail (P-8340, Sigma 1:100), and phosphatase inhibitor cocktail I and II (Sigma 1:100). Samples were subjected to 4-12% Bis-Tris gel electrophoresis (Invitrogen, Carlsbad, California, USA) and transferred to nitrocellulose membranes (Invitrogen). After 1 h incubation in 5% low-fat milk, membranes were probed with antibodies overnight at 41C followed by horseradish peroxidase-conjugated secondary antibody for 1 h at ambient temperature. The signal was detected by chemiluminescent reagents (SuperSignal, Pierce, Rockford, Illinois, USA). Nitrocellulose membranes were stripped with Re-Blot western blot recycling kit (Chemicon, Temecula, California, USA) and incubated with different antibodies. Antibodies used in this study included: p38a (Cell Signaling, Beverly, Massachusetts, USA, 1:2000), p38b (Zymed, San Francisco, California, USA, 1:1000), phospho-p38 (Cell Signaling, 1:1000), total p38 (Cell Signaling, 1:1000), COX-1 (Cayman, Ann Arbor, Michigan, USA, 1:1000), COX-2 (Cayman, 1:1000), and b-actin (Sigma, 1:50,000). Intensity of immunoreactive bands was quantified using ImageQuant software (Molecular Dynamics, Sunnyvale, California, USA) and was normalized relative to b-actin.
Statistics
For measurements of protein levels by western blotting and formalin test, four to seven animals were included per group. Groups were compared with one-way analysis of variance and Bonferroni post hoc test, or student's t-tests with a criterion of P value of less than 0.05 for significance.
Results
Downregulation of p38b, but not p38a, attenuates carrageenan-induced thermal hyperalgesia
Five days of IT treatment with a-AS (30 mg) or b-AS (30 mg) oligonucleotides suppressed spinal p38a and p38b protein expression as compared with respective protein in the control MS-treated animals, that is, 45% reduction of p38a protein, and 70% reduction of p38b protein (P < 0.05 vs. MS group) ( Fig. 1) .
Baseline latencies to thermal stimulation assessed before injection of carrageenan, were 8.9 ± 0.3 s for the MS group, a value that is not different from the baseline of intrathecally catheterized and naive animals (data not shown). Treatment with neither a-AS nor b-AS altered thermal baseline latencies (a-AS, 8.7 ± 0.3 s; and b-AS, 9.3 ± 0.3 s, n = 5-6 per group, P>0.05 vs. MS). In the MS group, paw withdrawal latency decreased to 2.4 ± 0.4 s at 120 min after carrageenan injection which is comparable with results observed in IT catheterized rats treated with IT saline (data not shown). The carrageenan-induced thermal hyperalgesia was unabated in IT MS and IT a-AS treated animals ( Fig. 2a ). In contrast, IT b-AS treatment produced a significant reduction in the thermal hyperalgesia (P<0.05, Fig. 2b ). The thermal withdrawal latency in the contralateral (nonhyperalgesic) paw was unaltered by AS treatment.
SP-induced spinal COX-2 expression is reversed by knockdown of either p38a or p38b protein
Eight hours after IT SP (60 nmol), COX-2 protein expression in spinal cord was increased while COX-1 protein levels remained the same (Fig. 3) . Unlike the effect of IT b-AS treatment in preventing hyperalgesia, upregulation of COX-2 protein in spinal cord was reversed by IT treatment with either b-AS or a-AS ( Fig. 3) . None of the AS treatment affected COX-1 protein expression ( Fig. 3 ). In addition, the SP-induced upregulation of COX-2 expression was prevented by IT pretreatment with p38ab inhibitor SB203580 (30 mg, 30 min before SP, data not shown).
Discussion
This study showed that IT p38a or p38b AS oligonucleotide treatment suppressed expression of the respective isoform in spinal cord. Reduction in the level of spinal p38b, but not p38a, prevented development of hyperalgesia after peripheral inflammation. Though the earlier studies with p38 inhibitors indicate that p38 is involved in inflammation-induced hyperalgesia, this study has further extended the earlier finding to reveal that it is the p38b, not p38a isoform, which contributes to spinal pain processing initiated by an inflammatory stimulus. In the case of upregulation of spinal COX-2 protein expression evoked by activation of the spinal neurokinin 1 (NK1) receptor [1, 8] , the observation that knockdown of either isoform is able to suppress induction of COX-2 protein production suggests that both p38a and p38b isoforms participate in transcriptional and/or translational regulation of spinal COX-2As it is known that COX-2 plays a pivotal role in maintenance of spinal sensitization, we hypothesize that p38a/b-mediated upregulation of spinal COX-2 is one of underlying mechanisms of persistent inflammation-associated hyperalgesia.
The unique effect of p38b in mediating the onset of hyperalgesia is an intriguing phenomenon. This finding with antihyperalgesic effect of p38b-AS on carrageenan inflammatory model extended the earlier reported work showing that specific knockdown of spinal p38b results in blockade of facilitated pain states which focused on acute models including formalin-evoked flinching (1 h) and IT SP-induced thermal hyperalgesia (< 0.5 h) [3] . In parallel, with these acute effects, an increase in phosphorylation of spinal p38 (P-p38) is seen as early as 5 min after IT SP or intraplantar formalin [1, 3] , and this phosphorylation is prevented when spinal p38b, but not p38a, is downregulated [3] . One important characteristic of p38b is the selective cellular location of this enzyme in spinal cord. Immunohistochemical studies revealed that p38b is present only in microglia [3] . Our earlier work has shown that carrageenan-induced increases in spinal P-p38 occurred exclusively in microglia. Treatment with minocycline, an inhibitor of microglia activation, at the IT dose that blocked carrageenan-induced hyperalgesia, also attenuated the increased P-p38 in microglia [9] . The current finding of the antihyperalgesic effect of p38b knockdown provides evidence for the hypothesis that p38b in microglia responds rapidly to afferent signals generated by peripheral inflammation, and that the p38b-mediated signal cascade is involved in the initial processing of spinal nociception.
It is widely accepted that COX-2 plays a critical role in the facilitation of spinal pain processing [10] . Although COX-2 is constitutively expressed in spinal cord, further upregulation of spinal COX-2 (both mRNA and protein) has been observed in a number of experimental models of hyperalgesia [11] [12] [13] [14] . It is shown that SP, the major neurotransmitter in primary afferents, is able to regulate COX-2 activity and expression through activation of NK1 receptors [1, 8] . As shown by our earlier work [1] spinal NK1 receptor activation-evoked synthesis of COX-2 protein is an acute event which can be prevented by IT pretreatment, but not posttreatment, with p38 inhibitors. This indicates that the role of p38 in the triggering of spinal COX-2 expression is immediate and transient. p38 regulation of spinal COX-2 likely occurs at the level of COX-2 mRNA transcription or stability through phosphorylation of transcription factors or indirectly through other kinases [15] . Indeed, p38 is known to activate transcription factors such as CREB and ATF-2, and bind to the CRE element in the promoter region of the COX-2 gene [16] . Together with other kinases, p38 regulates RNA stability of COX-2 mRNA by stimulating binding of mRNA-stabilizing factor HuR to AREs at the 3 0 -UTR [17] . Our finding that AS inhibition of either isoform partially prevents upregulation of COX-2 protein in spinal cord after NK1 activation suggests that both p38a and p38b isoforms may participate in the regulation of spinal COX-2 protein expression p38a is present in dorsal spinal cord and distinct from p38b its location is largely neuronal [3] . Spinal COX-2 is reportedly present in neurons, microglia, radial glia and endothelial cells [10] . Thus, it is possible that the two isoforms may participate in individual cell types. Synergy between these two isoforms may also exist, as it is known that activation of p38 in microglia promotes release of pronociceptive mediators, such as cytokines [18] , which further stimulate neurons and reinforce COX-2 expression.
Knockout of p38a or p38b genes has been reported. p38a deficiency was found to result in embryonic lethality [19] . Mice with p38b deficiency have been generated by two groups [4, 20] . Although both groups reported that inflammatory responses appear normal in p38b deficient mice, one group [20] did observe, in agreement with this report, that inflammation-induced hyperalgesia was attenuated. It appears that permanent elimination of one of the p38 isoforms may be associated with compensation of function and/or expression of other isoforms, including other mitogen-activated protein kinases (e.g. JNK, ERK) [4, 21] . Accordingly, these findings were achieved through the acute and specific knockdown of the two isoforms with IT AS, are the first tangible evidence suggesting that spinal p38a and b play distinct roles in acute spinal nociceptive processing and the delayed changes of protein expression induced by peripheral inflammation in the adult animals.
Conclusion
This study reveals the intriguing organization that acute activation of spinal p38 mitogen-activated protein kinase can lead to constitutive effects leading to an immediate hyperalgesia, and that the same isoform can participate in the initiation of long-term consequences such as the upregulation of an important proalgesic enzyme. Blocking this linkage preemptively can not only alter early changes in pain processing but diminish the long-term consequences otherwise associated with acute activation of the spinal systems which process nociceptive information. 
